Jack Khattar Sells 35,000 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Jack Khattar sold 35,000 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $50.37, for a total value of $1,762,950.00. Following the completion of the sale, the chief executive officer owned 958,100 shares of the company’s stock, valued at $48,259,497. This trade represents a 3.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Supernus Pharmaceuticals Trading Up 1.2%

SUPN stock opened at $50.82 on Wednesday. The stock’s 50 day simple moving average is $51.26 and its 200 day simple moving average is $49.17. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $59.68. The firm has a market cap of $2.93 billion, a P/E ratio of -74.73, a P/E/G ratio of 1.56 and a beta of 0.70.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on SUPN shares. Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Zacks Research lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Sunday, March 8th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Finally, Stifel Nicolaus upped their target price on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a report on Friday, December 19th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Supernus Pharmaceuticals has an average rating of “Hold” and a consensus price target of $62.17.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SUPN. Rubric Capital Management LP acquired a new position in Supernus Pharmaceuticals during the second quarter worth about $21,908,000. Woodline Partners LP lifted its holdings in Supernus Pharmaceuticals by 63.5% in the 3rd quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after acquiring an additional 490,835 shares during the last quarter. Bank of America Corp DE lifted its holdings in Supernus Pharmaceuticals by 67.1% in the 3rd quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock valued at $40,282,000 after acquiring an additional 338,584 shares during the last quarter. Morgan Stanley boosted its position in shares of Supernus Pharmaceuticals by 42.9% during the 4th quarter. Morgan Stanley now owns 1,079,471 shares of the specialty pharmaceutical company’s stock valued at $53,650,000 after purchasing an additional 324,154 shares in the last quarter. Finally, UBS Group AG boosted its position in shares of Supernus Pharmaceuticals by 137.6% during the 3rd quarter. UBS Group AG now owns 540,123 shares of the specialty pharmaceutical company’s stock valued at $25,812,000 after purchasing an additional 312,775 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.